​

Guardant Health (GH) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

GH Stock Forecast

Guardant Health stock forecast is as follows: an average price target of $41.75 (represents a 37.16% upside from GH’s last price of $30.44) and a rating consensus of 'Buy', based on 17 wall street analysts offering a 1-year stock forecast.

GH Price Target

The average price target for Guardant Health (GH) is $41.75 based on 1-year price targets from 17 Wall Street analysts in the past 3 months, with a price target range of $50.00 to $37.00. This represents a potential 37.16% upside from GH's last price of $30.44.

GH Analyst Ratings

Buy

According to 17 Wall Street analysts, Guardant Health's rating consensus is 'Buy'. The analyst rating breakdown for GH stock is 0 'Strong Buy' (0.00%), 16 'Buy' (94.12%), 1 'Hold' (5.88%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Guardant Health Price Target by Analyst

DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Aug 21, 2024Dan LeonardUBS$40.00$27.6844.51%31.41%
Aug 08, 2024Bill BonelloCraig-Hallum$37.00$31.3617.97%21.55%
Aug 08, 2024Tycho PetersonJefferies$40.00$33.9617.79%31.41%
Jul 29, 2024Mark MassaroBTIG$50.00$35.2841.72%64.26%
Jun 28, 2024Subbu NambiGuggenheim$36.00$28.8824.65%18.27%
Jun 04, 2024Kyle MiksonCanaccord Genuity$38.00$27.4138.64%24.84%
Jun 03, 2024Tycho PetersonJefferies$32.00$27.1018.08%5.12%
May 23, 2024Mark MassaroBTIG$45.00$22.5199.91%47.83%
May 22, 2024Kyle MiksonCanaccord Genuity$30.00$23.0130.38%-1.45%
Apr 24, 2024Chase KnickerbockerCraig-Hallum$28.00$17.9356.12%-8.02%
Sep 27, 2023David WestenbergPiper Sandler$40.00$27.5944.98%31.41%
Feb 06, 2023Goldman Sachs$45.00$29.5652.23%47.83%
Dec 16, 2022Tejas SavantMorgan Stanley$80.00$41.2693.89%162.81%
Dec 16, 2022Kyle MiksonCanaccord Genuity$65.00$41.2657.54%113.53%
Oct 05, 2022Mason CarricoStephens$99.00$59.7865.61%225.23%
Aug 08, 2022Goldman Sachs$80.00$54.2547.47%162.81%
May 09, 2022Julia QinJ.P. Morgan$125.00$39.32217.90%310.64%
Jun 03, 2021Matthew SykesGoldman Sachs$160.00$117.9035.71%425.62%

The latest Guardant Health stock forecast, released on Aug 21, 2024 by Dan Leonard from UBS, set a price target of $40.00, which represents a 44.51% increase from the stock price at the time of the forecast ($27.68), and a 31.41% increase from GH last price ($30.44).

Guardant Health Price Target by Period

1M3M12M
# Anlaysts--10
Avg Price Target--$37.60
Last Closing Price$30.44$30.44$30.44
Upside/Downside-100.00%-100.00%23.52%

In the current month, the average price target of Guardant Health stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Guardant Health's last price of $30.44. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

DateCompanyPrevious RatingNew RatingRating Change
Aug 21, 2024UBSBuyBuyHold
Aug 13, 2024Piper SandlerNeutralNeutralHold
Aug 08, 2024Cowen & Co.BuyBuyHold
Aug 08, 2024Craig-HallumBuyBuyHold
Aug 08, 2024JefferiesBuyBuyHold
Jul 29, 2024BTIGBuyBuyHold
Jul 29, 2024William BlairOutperformOutperformHold
Jun 28, 2024StephensBuyBuyHold
Jun 28, 2024JefferiesUnderperformUnderperformHold
Jun 28, 2024GuggenheimBuyUpgrade
Jun 04, 2024Canaccord GenuityBuyBuyHold
Jun 03, 2024JefferiesBuyInitialise
May 24, 2024StephensBuyBuyHold
May 24, 2024Piper SandlerUnderperformUnderperformHold
May 23, 2024BTIGBuyBuyHold
May 21, 2024Cowen & Co.BuyBuyHold
Feb 23, 2024William BlairOutperformOutperformHold
Nov 13, 2023Raymond JamesOutperformUpgrade
May 26, 2023Piper SandlerOverweightInitialise
Feb 06, 2023Goldman SachsBuyBuyHold
Jan 05, 2023ScotiabankSector OutperformInitialise
Oct 06, 2022StephensOverweightInitialise
Aug 08, 2022Goldman SachsBuyBuyHold
May 09, 2022J.P. MorganBuyBuyHold
Feb 24, 2022Wells FargoOverweightOverweightHold
Feb 24, 2022Morgan StanleyOverweightOverweightHold
Feb 24, 2022CitigroupBuyBuyHold
Feb 24, 2022SVB LeerinkOutperformOutperformHold

Guardant Health's last stock rating was published by UBS on Aug 21, 2024. The company gave GH a "Buy" rating, the same as its previous rate.

Guardant Health Financial Forecast

Guardant Health Revenue Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
Revenue-------------$143.03M$137.15M$128.71M$126.89M$117.40M$109.14M$96.10M$108.11M$94.78M$92.10M$78.67M$78.32M$74.57M$66.33M$67.51M$62.90M$60.85M
Avg Forecast$266.70M$257.32M$243.53M$228.98M$229.21M$218.44M$204.40M$190.50M$186.78M$170.49M$162.59M$150.09M$149.60M$137.35M$129.85M$117.87M$123.82M$117.75M$105.08M$95.77M$98.65M$92.01M$84.52M$73.75M$76.74M$65.93M$59.18M$56.48M$54.87M$45.41M
High Forecast$294.21M$283.86M$268.66M$252.60M$252.85M$240.97M$225.49M$198.27M$188.23M$170.54M$162.59M$150.64M$165.03M$137.35M$143.24M$130.03M$136.59M$117.75M$105.08M$95.77M$98.65M$92.01M$84.52M$73.75M$76.74M$65.93M$59.18M$56.48M$54.87M$45.41M
Low Forecast$258.79M$249.68M$236.31M$222.18M$222.41M$211.96M$198.34M$185.93M$185.01M$170.45M$162.59M$149.54M$145.16M$137.35M$125.99M$114.38M$120.15M$117.75M$105.08M$95.77M$98.65M$92.01M$84.52M$73.75M$76.74M$65.93M$59.18M$56.48M$54.87M$45.41M
# Analysts1075585411149991099988889991011159988
Surprise %-------------1.04%1.06%1.09%1.02%1.00%1.04%1.00%1.10%1.03%1.09%1.07%1.02%1.13%1.12%1.20%1.15%1.34%

Guardant Health's average Quarter revenue forecast for Dec 23 based on 10 analysts is $149.60M, with a low forecast of $145.16M, and a high forecast of $165.03M. GH's average Quarter revenue forecast represents a 4.59% increase compared to the company's last Quarter revenue of $143.03M (Sep 23).

Guardant Health EBITDA Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts1075585411149991099988889991011159988
EBITDA-------------$-113.54M$-119.62M$-132.65M$-138.69M$-151.43M$-219.56M$-115.41M$-84.17M$-101.24M$-91.22M$-103.89M$-84.14M$-76.63M$-48.90M$-22.90M$-19.73M$-9.76M
Avg Forecast$-201.20M$-194.12M$-183.72M$-172.74M$-172.91M$-164.79M$-154.20M$-143.71M$-140.91M$-128.62M$-122.65M$-139.64M$-112.86M$-103.62M$-97.96M$-126.95M$-113.52M$-96.13M$-85.79M$-115.41M$-80.54M$-75.12M$-69.00M$-80.55M$-62.65M$-53.83M$-48.32M$-28.78M$-44.80M$-37.07M
High Forecast$-195.23M$-188.36M$-178.27M$-167.62M$-167.78M$-159.90M$-149.63M$-140.26M$-139.57M$-128.58M$-122.65M$-111.71M$-109.51M$-103.62M$-95.05M$-101.56M$-90.81M$-96.13M$-85.79M$-92.33M$-80.54M$-75.12M$-69.00M$-64.44M$-62.65M$-53.83M$-48.32M$-23.02M$-44.80M$-37.07M
Low Forecast$-221.95M$-214.15M$-202.68M$-190.56M$-190.75M$-181.79M$-170.11M$-149.57M$-142.00M$-128.65M$-122.65M$-167.57M$-124.50M$-103.62M$-108.06M$-152.34M$-136.22M$-96.13M$-85.79M$-138.49M$-80.54M$-75.12M$-69.00M$-96.65M$-62.65M$-53.83M$-48.32M$-34.53M$-44.80M$-37.07M
Surprise %-------------1.10%1.22%1.04%1.22%1.58%2.56%1.00%1.05%1.35%1.32%1.29%1.34%1.42%1.01%0.80%0.44%0.26%

undefined analysts predict GH's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Guardant Health's previous annual EBITDA (undefined) of $NaN.

Guardant Health Net Income Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts1075585411149991099988889991011159988
Net Income-------------$-86.10M$-72.77M$-133.53M$-139.93M$-161.99M$-229.43M$-123.23M$-72.31M$-107.53M$-97.58M$-109.66M$-93.75M$-77.67M$-54.64M$-27.73M$-25.21M$-12.79M
Avg Forecast$-61.49M$-80.17M$-70.90M$-76.81M$-85.00M$-94.82M$-90.99M$-94.33M$-96.16M$-89.87M$-92.72M$-149.11M$-106.09M$-119.05M$-149.78M$-135.55M$-122.61M$-156.81M$-148.66M$-123.23M$-135.71M$-108.14M$-100.30M$-85.02M$-69.46M$-47.18M$-45.09M$-34.84M$-36.87M$-46.13M
High Forecast$-59.12M$-77.08M$-68.16M$-73.84M$-81.72M$-91.16M$-87.48M$-74.81M$-84.85M$-86.41M$-89.14M$-119.28M$-94.68M$-114.46M$-144.00M$-108.44M$-98.09M$-156.81M$-148.66M$-98.58M$-135.71M$-108.14M$-100.30M$-68.01M$-69.46M$-47.18M$-45.09M$-27.87M$-36.87M$-46.13M
Low Forecast$-69.73M$-90.93M$-80.40M$-87.11M$-96.40M$-107.54M$-103.19M$-121.97M$-103.70M$-101.93M$-105.15M$-178.93M$-115.21M$-135.02M$-169.86M$-162.66M$-147.13M$-156.81M$-148.66M$-147.87M$-135.71M$-108.14M$-100.30M$-102.02M$-69.46M$-47.18M$-45.09M$-41.81M$-36.87M$-46.13M
Surprise %-------------0.72%0.49%0.99%1.14%1.03%1.54%1.00%0.53%0.99%0.97%1.29%1.35%1.65%1.21%0.80%0.68%0.28%

Guardant Health's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. GH's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

Guardant Health SG&A Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts1075585411149991099988889991011159988
SG&A-------------$105.11M$112.56M$116.57M$119.31M$121.49M$117.28M$105.70M$99.87M$100.28M$96.09M$102.27M$100.79M$91.39M$62.20M$44.90M$41.15M$35.24M
Avg Forecast$245.02M$236.40M$223.74M$210.37M$210.58M$200.68M$187.79M$175.01M$171.60M$156.63M$149.37M$127.90M$137.44M$126.19M$119.29M$116.27M$113.75M$108.13M$96.49M$87.94M$90.59M$84.49M$77.61M$67.72M$70.47M$60.54M$54.34M$56.41M$50.39M$41.70M
High Forecast$270.30M$260.79M$246.82M$232.07M$232.30M$221.39M$207.16M$182.15M$172.94M$156.68M$149.37M$153.47M$151.62M$126.19M$131.60M$139.52M$125.49M$108.13M$96.49M$87.94M$90.59M$84.49M$77.61M$67.72M$70.47M$60.54M$54.34M$67.70M$50.39M$41.70M
Low Forecast$237.75M$229.39M$217.10M$204.13M$204.33M$194.73M$182.22M$170.81M$169.97M$156.59M$149.37M$102.32M$133.36M$126.19M$115.75M$93.02M$110.38M$108.13M$96.49M$87.94M$90.59M$84.49M$77.61M$67.72M$70.47M$60.54M$54.34M$45.13M$50.39M$41.70M
Surprise %-------------0.83%0.94%1.00%1.05%1.12%1.22%1.20%1.10%1.19%1.24%1.51%1.43%1.51%1.14%0.80%0.82%0.85%

Guardant Health's average Quarter SG&A projection for Dec 23 is $137.44M, based on 10 Wall Street analysts, with a range of $133.36M to $151.62M. The forecast indicates a 30.76% rise compared to GH last annual SG&A of $105.11M (Sep 23).

Guardant Health EPS Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts1075585411149991099988889991011159988
EPS-------------$-0.73$-0.67$-1.30$-1.36$-1.58$-2.25$-1.21$-0.71$-1.06$-0.96$-1.09$-0.94$-0.78$-0.57$-0.29$-0.27$-0.14
Avg Forecast$-0.50$-0.65$-0.58$-0.62$-0.69$-0.77$-0.74$-0.77$-0.78$-0.73$-0.75$-0.88$-0.86$-0.97$-1.22$-1.34$-1.40$-1.28$-1.21$-1.21$-1.11$-0.88$-0.82$-0.89$-0.57$-0.39$-0.37$-0.39$-0.30$-0.38
High Forecast$-0.48$-0.63$-0.55$-0.60$-0.66$-0.74$-0.71$-0.61$-0.69$-0.70$-0.72$-0.85$-0.77$-0.93$-1.17$-1.29$-1.35$-1.28$-1.21$-1.21$-1.11$-0.88$-0.82$-0.89$-0.57$-0.39$-0.37$-0.39$-0.30$-0.38
Low Forecast$-0.57$-0.74$-0.65$-0.71$-0.78$-0.87$-0.84$-0.99$-0.84$-0.83$-0.85$-1.00$-0.94$-1.10$-1.38$-1.52$-1.59$-1.28$-1.21$-1.21$-1.11$-0.88$-0.82$-0.89$-0.57$-0.39$-0.37$-0.39$-0.30$-0.38
Surprise %-------------0.75%0.55%0.97%0.97%1.23%1.85%1.00%0.64%1.20%1.17%1.23%1.66%2.02%1.55%0.74%0.90%0.37%

According to undefined Wall Street analysts, Guardant Health's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to GH previous annual EPS of $NaN (undefined).

Guardant Health Peer Comparison by Price Target

TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
MYGNMyriad Genetics$13.42$30.20125.04%Hold
CDNACareDx$21.09$37.5077.81%Buy
CSTLCastle Biosciences$26.83$40.5050.95%Buy
GHGuardant Health$30.44$41.7537.16%Buy
PSNLPersonalis$5.87$7.3825.72%Buy
DHRDanaher$231.10$289.5025.27%Buy
TMOThermo Fisher Scientific$526.07$640.8821.82%Buy
CRLCharles River Laboratories$186.16$209.0012.27%Buy
ILMNIllumina$135.27$147.789.25%Buy
AAgilent$135.54$147.408.75%Buy
NTRANatera$160.26$154.80-3.41%Buy
TWSTTwist Bioscience$48.17$46.00-4.50%Buy

GH Forecast FAQ

Is Guardant Health a good buy?

Yes, according to 17 Wall Street analysts, Guardant Health (GH) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 16 'Buy' recommendations, accounting for 94.12% of GH's total ratings.

What is GH's price target?

Guardant Health (GH) average price target is $41.75 with a range of $37 to $50, implying a 37.16% from its last price of $30.44. The data is based on 17 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Guardant Health stock go up soon?

According to Wall Street analysts' prediction for GH stock, the company can go up by 37.16% (from the last price of $30.44 to the average price target of $41.75), up by 64.26% based on the highest stock price target, and up by 21.55% based on the lowest stock price target.

Can Guardant Health stock reach $50?

GH's average twelve months analyst stock price target of $41.75 does not support the claim that Guardant Health can reach $50 in the near future.

What are Guardant Health's analysts' financial forecasts?

Guardant Health's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $842.54M (high $917.58M, low $818.63M), average EBITDA is $-636M (high $-618M, low $-692M), average net income is $-365M (high $-335M, low $-429M), average SG&A $774.06M (high $843M, low $752.1M), and average EPS is $-2.967 (high $-2.724, low $-3.487). GH's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $996.53M (high $1.1B, low $966.97M), average EBITDA is $-752M (high $-729M, low $-829M), average net income is $-289M (high $-278M, low $-328M), average SG&A $915.53M (high $1.01B, low $888.37M), and average EPS is $-2.352 (high $-2.261, low $-2.667).

Did the GH's actual financial results beat the analysts' financial forecasts?

Based on Guardant Health's last annual report (Dec 2022), the company's revenue was $449.54M, beating the average analysts forecast of $442.41M by 1.61%. Apple's EBITDA was $-651M, beating the average prediction of $-411M by 58.42%. The company's net income was $-655M, beating the average estimation of $-551M by 18.73%. Apple's SG&A was $463.78M, beating the average forecast of $406.32M by 14.14%. Lastly, the company's EPS was $-6.41, beating the average prediction of $-5.109 by 25.46%. In terms of the last quarterly report (Sep 2023), Guardant Health's revenue was $143.03M, beating the average analysts' forecast of $137.35M by 4.14%. The company's EBITDA was $-114M, beating the average prediction of $-104M by 9.58%. Guardant Health's net income was $-86.102M, missing the average estimation of $-119M by -27.68%. The company's SG&A was $105.11M, missing the average forecast of $126.19M by -16.70%. Lastly, the company's EPS was $-0.73, missing the average prediction of $-0.967 by -24.55%